“We’re delighted to have identified at least two proprietary Phylomers that represent the most potent inhibitors of MYC yet described. This outcome is a testament to the power of the Phylomer platform..."
"To date we’ve assayed less than 20% of the hits identified in the primary screens against MYC"
And this one is a pretty big statement, given the fuss that's gone on around MYC for years...
"Phylogica’s differentiation in the field of intracellular drug delivery now extends from best in class cell penetrating Phylomers for drug delivery to best in class active biologics drug compounds active against MYC.."
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)